Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace® 10 mg and Lipitor® 40 mg

This study is to compare the pharmacodynamics of a Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) and the respective reference products, atorvastatin (Lipitor®) 40 mg and ramipril (Altace®) 10 mg.

Study Overview

• Status: Unknown
• Conditions: Hypertension
• Intervention / Treatment: Drug: Cardiovascular Fixed Dose Combination Pill AAR; Drug: Atorvastatin 40 mg; Drug: Ramipril 10 mg

• Study Type: Interventional
• Enrollment (Anticipated): 528
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35209
      • Central Alabama Research
  • California
    • Los Angeles, California, United States, 90057
      • National Research Institute
    • Sacramento, California, United States, 95821
      • Clinical Trials Research
    • Tustin, California, United States, 92780
      • Clinical Trials Investigators, Inc
    • West Hills, California, United States, 91307
      • Infoshpere Clinical Research, Inc
  • Florida
    • Bradenton, Florida, United States, 34208
      • Meridien Research
    • Brandon, Florida, United States, 33511
      • PAB Clinical Research
    • Coral Gables, Florida, United States, 33134
      • Clinical Research of South Florida
    • Coral Gables, Florida, United States, 33134
      • Clinical Therapeutics Corporation
    • Doral, Florida, United States, 33166
      • Moonshine Research Center, Inc
    • Edgewater, Florida, United States, 32132
      • Riverside Clinical Research
    • Hialeah, Florida, United States, 33013
      • Nova Clinical Research Center Inc
    • Homestead, Florida, United States, 33030
      • Dr. John C. Gutleber Weight Loss, Beauty, and Family Practice
    • Jacksonville, Florida, United States, 32205
      • Westside Center for Clinical Research
    • Jacksonville, Florida, United States, 32216
      • Jacksonville Center for Clinical Research
    • Jupitor, Florida, United States, 33458
      • Health Awareness, Inc.
    • Kissimmee, Florida, United States, 34744
      • The Chappel Group Research
    • Lauderdale Lakes, Florida, United States, 33319
      • Sunrise Medical Center
    • Port Orange, Florida, United States, 32127
      • Progressive Medical Research
    • St. Petersburg, Florida, United States, 33709
      • Meridien Research
  • Illinois
    • Chicago, Illinois, United States, 60607
      • Cedar Crosse Research Center
  • Kentucky
    • Louisville, Kentucky, United States, 40213
      • Louisville Metabolic and Atherosclerosis Research
  • Louisiana
    • Monroe, Louisiana, United States, 71201
      • Clinical Trials of America LA, LLC
    • New Orleans, Louisiana, United States, 70124
      • DelRicht Research
  • Massachusetts
    • Watertown, Massachusetts, United States, 02472
      • Bay State Clinical Trials, Inc
  • Ohio
    • Perrysburg, Ohio, United States, 43551
      • Clinical Research Source
  • South Carolina
    • Lancaster, South Carolina, United States, 29720
      • Einstein Clinical Research
  • Texas
    • Carrollton, Texas, United States, 75006
      • Punzi Medical Center
    • Houston, Texas, United States, 77051
      • Cullen Research, LLC
    • Humble, Texas, United States, 77338
      • Research Trials Worldwide LLC
    • New Braunfels, Texas, United States, 78130
      • Central Texas Health Research
    • Plano, Texas, United States, 75093
      • Deleon Research, PLLC
    • San Antonio, Texas, United States, 78229
      • Diagnostics Research Group
    • San Antonio, Texas, United States, 78229
      • Sylvana Research
    • San Antonio, Texas, United States, 78228
      • Physician PrimeCare Research Institute, PLLC dba H
  • Utah
    • St. George, Utah, United States, 84790
      • Chysalis Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 74 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female patients aged ≥18 and <75 years.
• Patients with Stage 1 (SBP/DBP: 140-159/90-99 mmHg) or Stage 2 (SBP/DBP: ≥160/≥100 mmHg) hypertension, either untreated or after a wash out period.
• Patients with an LDL cholesterol level of ≥100 mg/dL and, either untreated or after the wash out period.
• Patients untreated with BP lowering and / or lipid lowering medication
• Patients treated with BP lowering and / or lipid lowering medication can be included if the medication can be safely withdrawn as per physician's judgment.
• Provide written informed consent.

Exclusion Criteria:

• Patients with a BMI of > 35
• SBP < 140 mmHg and DBP < 90 mmHg
• Severe hypertension defined as SBP > 180 mmHg and Diastolic Blood Pressure (DBP) > 110 mmHg
• LDL cholesterol level of <100 mg/dL, either untreated or after the wash out period.
• Serum triglyceride concentration ≥400 mg/dL, either untreated or after the wash out period.

• Patients with a medical condition requiring the chronic pharmacological treatments listed below:

  • Cytochrome P450 3A4 (CYP3A4) inhibitors (eg itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone).
  • Non-steroidal anti-inflammatory drugs (NSAIDs).
  • K-sparing diuretics.
  • Lithium.
  • Amiodarone and verapamil.
  • Oral anticoagulants (eg, warfarin).
  • Steroids.
  • Digoxin.
  • Gemfibrozil.
  • Niacin.
  • Potassium supplements.
  • Cyclosporine.
  • Danazol.
  • Rifampicin.
• Evidence of any known clinically significant chronic disease
• Patients with renal impairment with Creatinine Clearance (CrCl) < 40 mL/ min/ 1.73 m2
• Creatine phosphokinase (CPK) ≥5 x the upper limit of normal (ULN).
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x ULN.
• Total bilirubin ≥1.5 x ULN
• Medical history or evidence of drug or alcohol abuse.
• Medical history of gastrointestinal bleeding or gastroduodenal ulcer.
• Presence of secondary dyslipidemia.
• For patients on antihypertensive and/ or cholesterol lowering medication impossibility to withdraw it safely as per physician's judgment
• Previous coronary artery bypass graft (CABG).
• Previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting stent.
• Presence of severe congestive heart failure (New York Heart Classification (NYHC) III IV).
• Prior history of stroke, Transient Ischemic Attack (TIA), Myocardial Infarction (MI), and cardiomyopathy with systolic dysfunction (prior documented Left Ventricular Ejection Fraction (LVEF) < 40%)
• Aspirin induced asthma
• Previous intolerance and/or hypersensitivity to ACE inhibitors, statins and/or salicylates.
• Presence of unstable angina.
• Lab values other than specified out of the central laboratory normal range considered clinically significant.
• Patients and their partners not using effective contraception methods (i.e. intra uterine device (IUD) and condom or diaphragm with spermicide and condom) during the study and for at least one month thereafter, oral contraceptives are allowed.
• Pregnant, lactating, breastfeeding, or intends to become pregnant during the course of the study (females only). All women must have a negative urine pregnancy test at the Screening Visit, be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or have a postmenopausal status (no menses) for at least one year.
• Presence of mental illness limiting the capacity for self-care.
• Presence of major systemic illnesses: renal disease, liver disease, neurological or psychiatric disease.
• Participation, in the 30 days preceding enrolment into the study, in any other clinical study in which investigational or marketed drugs were employed.
• Any other medical condition that in the investigators opinion may interfere with the study procedures and/or evaluations.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: CV Fixed Dose Combination Pill AAR; Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).	Drug: Cardiovascular Fixed Dose Combination Pill AAR; A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
ACTIVE_COMPARATOR: Atorvastatin; Atorvastatin 40 mg (Lipitor®).	Drug: Atorvastatin 40 mg; A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
ACTIVE_COMPARATOR: Ramipril; Ramipril 10 mg (Altace®).	Drug: Ramipril 10 mg; A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Difference in the adjusted mean 24-h systolic blood pressure results using ABPM between the baseline (week 0) and the final visit (week 8).	Measures at baseline visit (week 0) and final visit (week 8).
Difference in LDL cholesterol levels between the baseline (week 4) and the final visit (week 8).	Measures at baseline visit (week 4) and final visit (week 8).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in the adjusted mean 24-h diastolic blood pressure results (using ABPM) between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Difference in the adjusted mean 24-h mean arterial pressure results (using ABPM) between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Difference in the adjusted mean 24-h heart rate results (using ABPM) between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Difference in Very Low-Density Lipoprotein (VLDL) cholesterol levels between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Difference in HDL cholesterol levels between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Difference in total cholesterol levels between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Difference in triglyceride levels between the basal and the final visits.		Measures at baseline visit (week 0) and final visit (week 8).
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	AEs, clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), vital signs, electrocardiogram (ECG), and physical examination. The total number of patients with at least one AE and the number of AEs will be included in listings and tabulations. AEs will be coded using MedDRA, classified by system organ class (SOC) and preferred term and tabulated by intensity and causal relationship for each treatment.	Through study completion, an average of 3 months.

Collaborators and Investigators

• Sponsor: Ferrer Internacional S.A.

Study record dates

Study Major Dates

• Study Start: March 1, 2016
• Primary Completion (ANTICIPATED): October 1, 2017
• Study Completion (ANTICIPATED): October 1, 2017

Study Registration Dates

• First Submitted: February 15, 2016
• First Submitted That Met QC Criteria: June 6, 2016
• First Posted (ESTIMATE): June 7, 2016

Study Record Updates

• Last Update Posted (ACTUAL): April 10, 2017
• Last Update Submitted That Met QC Criteria: April 7, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Hypertension; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Enzyme Inhibitors; Antimetabolites; Protease Inhibitors; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Ramipril
• Other Study ID Numbers: FCD-PP-1501

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO